Abbreviations
tumor, indexCharlson comorbidity, Cancer
ADVERSE EVENT, TUMOR, CANCER
docetaxel and cisplatincisplatin and 5-fluorouracilconcurrent chemoradiotherapyesophageal squamous cell carcinomaoverall survivalprogression free survivalesophageal carcinomaoverall response ratecomplete remissionpartial remissionSun Yat-sen University Cancer CenterKarnofsky performance statusAmerican Joint Committee on Cancercomputed tomographypositron emission tomographygross tumor volumeinvolved field irradiationclinical target volumeplanning target volumeintensity-modulated radiation therapythree-dimensional conformal radiotherapyCommon Terminology Criteria for Adverse Events version 3.0fluorouracil plus leucovorin and oxaliplatinadverse eventbody mass indexCharlson comorbidity indexstable diseaseprogressive disease5-fluorouracil + irinotecan + leucovorinanti-program death-1adenocarcinomamedian survival timeevery weekevery three weeksevery four weeksevery five weeksradiotherapysquamous cell carcinomapaclitaxel + cisplatinpaclitaxel + fluorouracilpaclitaxel + carboplatinfluorouracil + cisplatin + paclitaxelsalvage Endoscopic mucosal resectionsalvage endoscopic submucosal dissectionsalvage photodynamic therapysalvage Argon plasma coagulationnon-radiotherapybiological effective dosecisplatindocetaxelfraction